|
TR199900191T2
(xx)
*
|
1996-07-29 |
1999-04-21 |
Warner-Lambert Company |
(S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses.
|
|
ES2183587T3
(es)
*
|
1998-07-24 |
2003-03-16 |
Samsung Fine Chemicals Co Ltd |
Procedimiento continuo para la preparacion de derivados de acido (s) -3-4-dihidroxibutirico opticamente puros..
|
|
US6713290B2
(en)
|
1998-07-24 |
2004-03-30 |
Samsung Fine Chemicals Co., Ltd. |
Process for preparing optically pure (S)-3-hydroxy-γ-butyrolactone
|
|
KR100332703B1
(ko)
*
|
1998-07-24 |
2002-08-27 |
삼성정밀화학 주식회사 |
광학활성을갖는(s)-3,4-에폭시부티르산염의제조방법
|
|
US6235930B1
(en)
*
|
1999-03-31 |
2001-05-22 |
Board Of Trustees Operating Michigan State University |
Process for the preparation of 3,4-dihydroxybutanoic acid and derivatives thereof from substituted pentose sugars
|
|
HU227840B1
(en)
*
|
1999-05-06 |
2012-05-02 |
Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag |
Intermediates of atorvastatin synthesis and process for producing them
|
|
ES2258030T3
(es)
|
1999-12-17 |
2006-08-16 |
Pfizer Science And Technology Ireland Limited |
Procedimiento para producir atorvastatina calcio cristalina.
|
|
EP1584616A1
(en)
|
1999-12-17 |
2005-10-12 |
Pfizer Science and Technology Ireland Limited |
Industrial process for the production of crystalline atorvastatin trihydrate hemi calcium salt
|
|
JP4598917B2
(ja)
*
|
2000-04-28 |
2010-12-15 |
ダイセル化学工業株式会社 |
ラクトンの製造方法
|
|
KR100645665B1
(ko)
|
2000-07-27 |
2006-11-13 |
에스케이 주식회사 |
(ｓ)-베타-하이드록시-감마-부티로락톤의 연속 제조방법
|
|
US6476235B2
(en)
|
2001-01-09 |
2002-11-05 |
Warner-Lambert Company |
Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
|
|
EP1734034A3
(en)
|
2001-01-09 |
2007-01-03 |
Warner-Lambert Company LLC |
Carboxylic acid salts of beta-alanine esters or -amides
|
|
WO2002057229A1
(en)
*
|
2001-01-19 |
2002-07-25 |
Biocon India Limited |
FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
|
|
BR0210666A
(pt)
|
2001-06-29 |
2004-10-05 |
Warner Lambert Co |
Formas cristalinas do sal de cálcio do ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-dihidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)c arbonil]-1h-pirrol-1-heptanóico (2:1) (atorvastatina)
|
|
MXPA03012045A
(es)
*
|
2001-07-06 |
2004-03-29 |
Teva Pharma |
Proceso para preparar derivados del acido 7-amino sin 3,5-dihidroxi heptanoico a traves de derivados del acido 6-ciano sin 3,5-dihidroxi hexanoico.
|
|
BR0215602A
(pt)
*
|
2002-02-25 |
2004-12-07 |
Biocon Ltd |
ésteres de boronato
|
|
GB0211716D0
(en)
|
2002-05-22 |
2002-07-03 |
Phoenix Chemicals Ltd |
Process
|
|
CN100357289C
(zh)
|
2002-08-06 |
2007-12-26 |
沃尼尔·朗伯有限责任公司 |
制备5－(4－氟苯基)－1－[2－((2r,4r)－4－羟基－6－氧代－四氢－吡喃－2－基)乙基]－2－异丙基－4－苯基－1h－吡咯－3－羧酸苯基酰胺的方法
|
|
EP1558597B1
(en)
*
|
2002-09-18 |
2008-05-07 |
SK Holdings Co., Ltd. |
Continuous process for the production of optically pure (s)-beta hydroxy-gamma-butyrolactone
|
|
AU2003263031A1
(en)
*
|
2002-09-20 |
2004-04-08 |
Diversa Corporation |
Chemoenzymatic methods for the synthesis of statins and stain intermediates
|
|
US6713639B1
(en)
|
2002-10-28 |
2004-03-30 |
Council Of Scientific And Industrial Research |
Process for preparing enantiomerically pure (S)-3-hydroxy-gamma-butyrolactone
|
|
EP1615883A1
(en)
*
|
2003-04-14 |
2006-01-18 |
Warner-Lambert Company |
Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
|
|
ES2323366T3
(es)
*
|
2003-04-22 |
2009-07-14 |
Biocon Limited |
Procedimiento novedoso para la reduccion estereoselectiva de beta-cetoesteres.
|
|
US7790197B2
(en)
*
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US7655692B2
(en)
*
|
2003-06-12 |
2010-02-02 |
Pfizer Inc. |
Process for forming amorphous atorvastatin
|
|
US20040253305A1
(en)
*
|
2003-06-12 |
2004-12-16 |
Luner Paul E. |
Pharmaceutical compositions of atorvastatin
|
|
US20050271717A1
(en)
*
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
CN101318923A
(zh)
*
|
2003-09-17 |
2008-12-10 |
沃尼尔·朗伯有限责任公司 |
[R－(R*,R*)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯基氨基)羰基]－1H－吡咯－1－庚酸的结晶形式
|
|
WO2005068642A2
(en)
|
2003-10-01 |
2005-07-28 |
Board Of Trustees Operating Michigan State University |
Bacterial synthesis of 1,2,4-butanetriol enantiomers
|
|
CN1960972A
(zh)
*
|
2004-04-16 |
2007-05-09 |
辉瑞产品公司 |
用于形成无定形阿托伐它汀钙的方法
|
|
CA2649054A1
(en)
|
2004-05-05 |
2005-11-10 |
Pfizer Products Inc. |
Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
|
|
JP2008506764A
(ja)
|
2004-07-20 |
2008-03-06 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
|
|
WO2006046109A1
(en)
|
2004-10-28 |
2006-05-04 |
Warner-Lambert Company Llc |
Process for forming amorphous atorvastatin
|
|
JP2008521878A
(ja)
*
|
2004-12-02 |
2008-06-26 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
非晶質アトルバスタチンの医薬組成物及びその製造のための方法
|
|
DE602006013815D1
(de)
*
|
2005-05-31 |
2010-06-02 |
Kowa Co |
Verfahren zur herstellung von optisch aktiven ppar-aktivierenden verbindungen und zwischenprodukte für die herstellung
|
|
CA2547216A1
(en)
*
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
|
ATE466840T1
(de)
|
2005-11-21 |
2010-05-15 |
Warner Lambert Co |
Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
|
|
US20110165641A1
(en)
*
|
2006-03-31 |
2011-07-07 |
The Board Of Trustees Of Michigan State University |
Synthesis of 1,2,4-Butanetriol Enantiomers from Carbohydrates
|
|
WO2008091288A2
(en)
*
|
2006-07-19 |
2008-07-31 |
Board Of Trustees Of Michigan State University |
Microbial synthesis of d-1,2,4-butanetriol
|
|
KR100850558B1
(ko)
|
2008-01-02 |
2008-08-06 |
조동옥 |
아토르바스타틴의 효율적인 제조방법
|
|
JP2009256316A
(ja)
|
2008-03-28 |
2009-11-05 |
Daicel Chem Ind Ltd |
β−ヒドロキシ−γ−ブチロラクトンの製造方法
|
|
CN101337906B
(zh)
*
|
2008-08-15 |
2012-06-27 |
河南豫辰精细化工有限公司 |
一种4-甲基-3-氧代-n-苯基戊酰胺的制备方法
|
|
EP2327682A1
(en)
|
2009-10-29 |
2011-06-01 |
KRKA, D.D., Novo Mesto |
Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
|
|
EP2373609B1
(en)
|
2008-12-19 |
2013-10-16 |
KRKA, D.D., Novo Mesto |
Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
|
|
US20140335179A1
(en)
|
2011-07-01 |
2014-11-13 |
Dsm Sinochem Pharmaceuticals Netherlands B.V. |
Micronized crystals of atorvastatin hemicalcium
|
|
CN106397241A
(zh)
*
|
2016-08-23 |
2017-02-15 |
杨锋 |
一种4‑甲基‑3‑氧代‑n‑苯基戊酰胺的绿色环保后处理方法
|
|
CN106588689A
(zh)
*
|
2016-12-15 |
2017-04-26 |
河南豫辰药业股份有限公司 |
一种从结晶母液废液中回收阿托伐他汀中间体m4的方法
|
|
CN112939901B
(zh)
*
|
2021-02-09 |
2023-05-09 |
中国科学院福建物质结构研究所 |
一种α-羟基-γ-丁内酯的制备方法
|
|
CN114195670B
(zh)
*
|
2021-12-31 |
2024-03-15 |
河南豫辰药业股份有限公司 |
一种阿托伐他汀母核m4的精制方法
|
|
CN117447350B
(zh)
*
|
2023-10-26 |
2026-02-13 |
河南豫辰药业股份有限公司 |
一种阿托伐他汀m4有机废物综合再利用方法
|